Table 4 Stratified analysis of lncRNA MALAT1 rs3200401 genotypes associated with advanced NSCLC patients’ survival
Variables | Adenocarcinoma | Squamous cell carcinoma | ||
|---|---|---|---|---|
Adjusted HR (95% CI)a CT + TT vs. CC | P a | Adjusted HR (95% CI)a CT + TT vs. CC | P a | |
Age | ||||
 ≤65 | 0.59 (0.35–1.00) | 0.054 | 1.32 (0.69–2.53) | 0.397 |
 >65 | 0.94 (0.51–1.74) | 0.850 | 0.95 (0.53–1.69) | 0.862 |
Sex | ||||
 Male | 0.66 (0.42–1.05) | 0.081 | 1.04 (0.67–1.63) | 0.857 |
 Female | 0.64 (0.26–1.54) | 0.317 | --- | --- |
Smoking | ||||
 Never | 0.44 (0.18–1.10) | 0.079 | 16.73 (0.10–2963.81) | 0.285 |
 Ever | 0.73 (0.46–1.15) | 0.170 | 1.01 (0.65–1.60) | 0.933 |
TNM Stage | ||||
 IIIA-IIIB | 0.54 (0.29–1.01) | 0.053 | 1.08 (0.65–1.79) | 0.779 |
 IV | 0.83 (0.48–1.41) | 0.484 | 0.91 (0.42–1.96) | 0.810 |
Surgical operation | ||||
 No | 0.69 (0.42–1.13) | 0.137 | 0.99 (0.61–1.63) | 0.982 |
 Yes | 0.56 (0.27–1.16) | 0.118 | 1.12 (0.50–2.51) | 0.792 |
Chemotherapy or Radiotherapy | ||||
 No | 0.47 (0.05–4.55) | 0.516 | 4.73 (0.35–63.42) | 0.241 |
 Yes | 0.71 (0.47–1.07) | 0.098 | 1.07 (0.70–1.65) | 0.753 |